Market Place
Sourcing Support
All News #Library
Biotech
Plus Therapeutics Starts GMP Trial Prep Manufacturing
24 Apr 2026 //
FIRSTWORD PHARMA
Plus Therapeutics, SpectronRx Partner for REYOBIQ Trial
23 Apr 2026 //
GLOBENEWSWIRE
Plus Therapeutics Names Eric J. Daniels Chief Development Officer
09 Apr 2026 //
GLOBENEWSWIRE
Radiotherapeutics Moment: Isotopes are Changing Cancer Treatment
02 Apr 2026 //
BIOSPACE
Plus Therapeutics Advances REYOBIQ for Leptomeningeal Metastases
08 Jan 2026 //
GLOBENEWSWIRE
Plus Therapeutics Highlights 3 REYOBIQ Data at 2025 SNO Meeting
04 Dec 2025 //
GLOBENEWSWIRE
Plus Therapeutics To Unveil Respect Phase 1 Study Results
01 Dec 2025 //
GLOBENEWSWIRE
Plus Therapeutics Concludes FDA Meeting On REYOBIQ Development
24 Nov 2025 //
GLOBENEWSWIRE
Plus Therapeutics Updates On Cnside® Diagnostic Platform Launch
21 Oct 2025 //
GLOBENEWSWIRE
Plus Therapeutics unveils REYOBIQ™ trial success
18 Aug 2025 //
GLOBENEWSWIRE
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data
20 Nov 2023 //
GLOBENEWSWIRE
Plus Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT
29 Jun 2023 //
GLOBENEWSWIRE
Plus Therapeutics Announces Topline Results from Glioblastoma at ASCO 2023
30 May 2023 //
GLOBENEWSWIRE
Plus Announces 1st Patient Dosed in ReSPECT-GBM Ph2b Trial of Rhenium Obisbemeda
18 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.